10 protocol(s) meet the specified criteria
PI: Grilley-Olson, Juneko
Protocol No.TitleStatus
C-145-03A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-145) for the Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and NeckOpen
EAY131-AMATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard TreatmentOpen
EAY131-CIRBMolecular Analysis of Therapy Choice (MATCH)Open
EAY131-EMATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFROpen
EAY131-K1Phase 2 Study of JNJ-42756493 (Erdafitinib) in Patients with Tumors with FGFR AmplificationsOpen
EAY131-K2Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol K2: EAY131-K2: Phase 2 Study of JNJ-42756493 (Erdafitinib)in Patients with Tumors with FGFR Mutations or Fusions.Open
EAY131-Z1GMolecular Analysis of Therapy Choice (MATCH): EAY131-Z1G: Phase II Study of Copanlisib in Patients with Tumors with PTEN Loss by IHC and any PTEN Sequencing ResultOpen
EAY131-Z1HMolecular Analysis of Therapy Choice (MATCH) EAY131-Z1H: Phase II Study of Copanlisib in Patients with Tumors with Deleterious PTEN Sequencing Reuslt and PTEN Expression by IHCOpen
ML28897PRO/02My Pathway: An Open-Label Phase IIA Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, and Vismodegib in Patients who have Advanced Solid Tumors with Mutations or Gene Expression Abnormalities Predictive of Response to one of these Agents.Open
NC-6300-001A Phase 1b/2 Dose-Escalation and Expansion Trial of NC-6300 (Nanoparticle Epirubicin) in Patients with Advanced Solid Tumors or Advanced, Metastatic, or Unresectable Soft Tissue SarcomaOpen